Variables Period Placebo group1 (n=21) Intervention group (n=22) MD (95%CI) between groups
TAC (mmol/L) Initial 0.95 (0.10) 0.80 (0.15) -0.15 ( -0.56 to 0.10)
End 1.10 (0.10) 1.45 (0.35) a , b 0. 35 (0. 10 to 0.43)
MD (95% CI) within groups 0.15 (-0.31 to 0. 20) 0.65 (-0.82 to -0. 50)
SOD (U/mg Hb) Initial 1627.32 (142.90) 1604.75 (97.21) -22.55(-52.20 to 97.35)
End 1609.65 (154.25) 1774.20 (105.50) a, b 165.50 (84.8 to 109.9)
MD (95% CI) within groups -17.98 (-42.57 to 78.55) 169.45 (-218.40 to -121.20)
GSH-Px (U/g Hb) Initial 33.53 (3.0) 32.96 (2.31) 0.60 (-1.07 to 2.21)
End 33.45 (3.34) 35.60 (3.65) a 2.15 (-4.30 to 0.32)
MD (95% CI) within groups -0.08 (-0.70 to 0.85) 2.64 (-3.99 to -1.25)
Catalase (U/g Hb) Initial 64.20 (18.17) 59.70 (17.20) -4. 50 (-3.20 to 17.50)
End 66.79 (16.60) 73.60 (26.55) 6.81 (-23.46 to 4.70)
MD (95% CI) within groups 2.59 (-7.93 to 13.15) -13.90 (-23.65 to 4.12)
Uric acid (mg/dL) Initial 4.60 (1.26) 4.75 (1.23) 0.15 (-0.91 to 0.62)
End 4.50 (1.33) 4.80 (1.20) 0.40 (-1.10 to 0.45)
MD (95% CI) within groups -0.10 (-0.14 to 0..40) 0.15 (-0.39 to 0.26)
MDA (nmol/mL) Initial 3.85 (0.84) 3.64 (1.42) -0.25 (-0.56 to 0.93)
End 3.68 (0.68) 2.99 (1.16) a , b -0.70 (-0.25 to -1.20)
MD (95% CI) within groups -0.17 (-0.23 to 0.56) -0.65 (-0.50 to -1.21)
8-iso-PGF2α (pg/ml) Initial 33.60 (7.03) 30.15 (4.50) -3.30 (-11.80 to 6.50)
End 31.20 (5.15) 25.10 (4.15) a , b -6.65 (-8.45 to -5.40)
MD (95% CI) within groups -2.4.0 (-9.15 to 8.20) -4.90 (-8.05 to -4.60)